Immune Checkpoint Inhibitors: The Emerging Cornerstone in Cholangiocarcinoma Therapy?
Background: Cholangiocarcinoma (CCA) encompasses a heterogeneous group of malignant tumors with dismal prognosis and increasing incidence worldwide. Both late diagnosis due to the lack of early symptoms and the refractory nature of these tumors seriously compromise patients’ welfare and outcomes. Su...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2021-09-01
|
Series: | Liver Cancer |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/518104 |